Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Metabolic alterations are increasingly recognized as important novel anti‐cancer targets. Among several regulators of metabolic alterations, fructose 2,6 bisphosphate (F2,6BP) is a critical glycolytic regulator. Inhibition of the active form of PFKFB3 ser461 using a novel inhibitor, PFK158 resulted in reduced glucose uptake, ATP production, lactate release as well as induction of apoptosis in gynecologic cancer cells. Moreover, we found that PFK158 synergizes with carboplatin (CBPt) and paclitaxel (PTX) in the chemoresistant cell lines, C13 and HeyA8MDR but not in their chemosensitive counterparts, OV2008 and HeyA8, respectively. We determined that PFK158‐induced autophagic flux leads to lipophagy resulting in the downregulation of cPLA2, a lipid droplet (LD) associated protein. Immunofluorescence and co‐immunoprecipitation revealed colocalization of p62/SQSTM1 with cPLA2 in HeyA8MDR cells uncovering a novel pathway for the breakdown of LDs promoted by PFK158. Interestingly, treating the cells with the autophagic inhibitor bafilomycin A reversed the PFK158‐mediated synergy and lipophagy in chemoresistant cells. Finally, in a highly metastatic PTX‐resistant in vivo ovarian mouse model, a combination of PFK158 with CBPt significantly reduced tumor weight and ascites and reduced LDs in tumor tissue as seen by immunofluorescence and transmission electron microscopy compared to untreated mice. Since the majority of cancer patients will eventually recur and develop chemoresistance, our results suggest that PFK158 in combination with standard chemotherapy may have a direct clinical role in the treatment of recurrent cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Drug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739
Autophagy regulates lipid metabolism
Singh, R., Kaushik, S., Wang, Y., Xiang, Y., Novak, I., Komatsu, M., Tanaka, K., Cuervo, A. M., & Czaja, M. J. (2009) · Nature · doi:10.1038/nature07976 · Cited by 3,975
Self-citationMonoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis
Nomura, D. K., Long, J. Z., Niessen, S., Hoover, H. S., Ng, S.-W., & Cravatt, B. F. (2010) · Cell · doi:10.1016/j.cell.2009.11.027 · Cited by 1,002 · cited 1×
“Thus, cancer cells utilize both lipogenic and lipolytic pathways to acquire fatty acids(13) which, in turn, promote cancer cell proliferation and survival.(14,15) Interestingly, LD-rich cancer cells also exhibit resistance to chemotherapeutic agents which suggests a crucial role of lipids in drug resistance.”
BackgroundRegulation of lipid stores and metabolism by lipophagy
Liu, K., & Czaja, M. J. (2013) · Cell Death & Differentiation · doi:10.1038/cdd.2012.63 · Cited by 542
Lipoprotein lipase links dietary fat to solid tumor cell proliferation
Kuemmerle, N. B., Rysman, E., Lombardo, P. S., Flanagan, A. J., Lipe, B. C., Wells, W. A., Pettus, J. R., Froehlich, H. M., Memoli, V. A., Morganelli, P. M., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0802 · Cited by 286 · cited 1×
“Thus, cancer cells utilize both lipogenic and lipolytic pathways to acquire fatty acids(13) which, in turn, promote cancer cell proliferation and survival.(14,15) Interestingly, LD-rich cancer cells also exhibit resistance to chemotherapeutic agents which suggests a crucial role of lipids in drug resistance.”
Background
Cited by
Modulating Glycolysis to Improve Cancer Therapy
Chelakkot, C., Chelakkot, V. S., Shin, Y., & Song, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032606 · Cited by 374
Zhang, S., Peng, X., Yang, S., Li, X., Huang, M., Wei, S., Liu, J., He, G., Zheng, H., Yang, L., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-04593-3 · Cited by 306
Self-citationLiao, M., Yao, D., Wu, L., Luo, C., Wang, Z., Zhang, J., & Liu, B. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.12.003 · Cited by 261
The metabolic landscape of lung cancer: New insights in a disturbed glucose metabolism
Vanhove, K., Graulus, G.-J., Mesotten, L., Thomeer, M., Derveaux, E., Noben, J.-P., Guedens, W., & Adriaensens, P. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01215 · Cited by 147
Ma, Y., Wang, W., Idowu, M. O., Oh, U., Wang, X.-Y., Temkin, S. M., & Fang, X. (2018) · Cancers · doi:10.3390/cancers11010033 · Cited by 145
“Numerous glycolytic enzymes such as HK-2, PFK2, PKM2, LDHA, and PDK, have been reported to be Cancers 2019, 11, 33 10 of 16 rate-limiting factors that are dysregulated in various types of cancer [49].”
Background
Metadata
- Authors
- Mondal, S., Roy, D., Sarkar Bhattacharya, S., Jin, L., Jung, D., Zhang, S., Kalogera, E., Staub, J., Wang, Y., Xuyang, W., Khurana, A., Chien, J., Telang, S., Chesney, J., Tapolsky, G., Petras, D., & Shridhar, V.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2018-10-30
- Volume
- 144
- Issue
- 1
- Pages
- 178-189
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2891973735
- Cited by
- 151
- References
- 6
- FWCI
- 3.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers. https://app.cochat.ai/papers/10.1002/ijc.31868
- The paper
- Mondal, S., Roy, D., Sarkar Bhattacharya, S., Jin, L., Jung, D., Zhang, S., Kalogera, E., Staub, J., Wang, Y., Xuyang, W., Khurana, A., Chien, J., Telang, S., Chesney, J., Tapolsky, G., Petras, D., & Shridhar, V. (2019). Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers. International Journal of Cancer. https://doi.org/10.1002/ijc.31868
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.